抗PD-1治疗后丧失主要组织相容性复合体I类表达的转移性黑色素瘤病灶中肿瘤浸润淋巴细胞的肿瘤反应性分析
本文报告一例55岁女性转移性黑色素瘤患者,经抗PD-1抗体治疗12个月肿瘤抑制成功后,一处病灶再次生长。切除两处病灶后发现复发灶肿瘤细胞完全丧失主要组织相容性复合体I类表达,经逆转录病毒转导正常β2-微球蛋白基因后恢复。来自复发灶的肿瘤浸润淋巴细胞不能识别原肿瘤细胞,但能强效识别恢复主要组织相容性复合体I类表达的细胞。
要点
- 抗PD-1治疗后延迟复发灶肿瘤细胞可完全丧失主要组织相容性复合体I类表达。
- 来自复发灶的肿瘤浸润淋巴细胞不能识别原肿瘤细胞。
- 转导正常β2-微球蛋白基因恢复主要组织相容性复合体I类表达后,肿瘤浸润淋巴细胞可强效识别。
核心结论
- 本报告强调基于T细胞免疫治疗的局限性,并突出为此类病例开发替代策略的重要性。
研究设计与样本
- 本篇为病例报告,报告一例55岁女性转移性黑色素瘤患者的两处转移病灶。
主要发现
- 抗PD-1抗体治疗12个月肿瘤抑制成功后,一处病灶开始再次生长。
- 缩小病灶由坏死组织和巨噬细胞组成,增大病灶由坏死组织和存活肿瘤细胞组成。
- 增大病灶肿瘤细胞完全丧失主要组织相容性复合体I类表达,经逆转录病毒转导正常β2-微球蛋白基因后恢复。
- 来自复发灶的肿瘤浸润淋巴细胞不能识别该病灶来源的原肿瘤细胞,但经β2-微球蛋白转导恢复主要组织相容性复合体I类表达的细胞被强效识别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti-PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti-PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I-recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell-based immunotherapy and highlights the importance of developing alternative strategies for such cases.
引用
- Inozume T, Yaguchi T, Ariyasu R, et al. Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy. J Invest Dermatol. 2019. PMID: 30684558. doi:10.1016/j.jid.2019.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。